Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Continuing Operations (2020 - 2023)

Cullinan Therapeutics has reported Income from Continuing Operations over the past 4 years, most recently at 25563000.0 for Q4 2023.

  • Quarterly results put Income from Continuing Operations at 25563000.0 for Q4 2023, up 5.63% from a year ago — trailing twelve months through Dec 2023 was 155101000.0 (down 242.04% YoY), and the annual figure for FY2025 was 219879000.0, down 31.21%.
  • Income from Continuing Operations for Q4 2023 was 25563000.0 at Cullinan Therapeutics, up from 39183000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CGEM hit a ceiling of 174065000.0 in Q2 2022 and a floor of 58141000.0 in Q1 2023.
  • Median Income from Continuing Operations over the past 4 years was 21574500.0 (2021), compared with a mean of 10802375.0.
  • Peak annual rise in Income from Continuing Operations hit 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
  • Cullinan Therapeutics' Income from Continuing Operations stood at 29094000.0 in 2020, then fell by 17.57% to 34206000.0 in 2021, then grew by 20.81% to 27088000.0 in 2022, then increased by 5.63% to 25563000.0 in 2023.
  • The last three reported values for Income from Continuing Operations were 25563000.0 (Q4 2023), 39183000.0 (Q3 2023), and 32214000.0 (Q2 2023) per Business Quant data.